Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative
ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number
jumped to more than 5,500.
As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients.
Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors.
In this article, we will share the tried-and-true tactics to build a strong pharma brand.
Get creative with interactive email marketing
One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the
audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning
out generic emails with artificial intelligence tools.
Palbace 125 Mg Capsules Suppliers-exporters India , Palbace a 125Mg Capsule is employed within the treatment of carcinoma. It's additionally wont to treat patients with bound varieties of carcinoma (estrogen receptor-positive, human stratum protein receptor 2-negative) that have unfold to alternative organs. it's given in conjunction with secretion malignant tumor therapies.
We are leading suppliers & exporters of "Palbace 125Mg" in China, Russia, Hongkong, Bulgaria, Romania, India. We're largest suppliers of Pfizer India medicines & provide you the best price on Palbace 125Mg.
The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us.
Buy Online Palbace 125Mg Suppliers Price India
Palbace 125Mg suppliers India
Palbace 125mg Capsules
Palbace (known as IBRANCE in other parts of
the world) or palbociclib by Pfizer is a cancer drug that interferes with the growth and spread of cancer cells in the body.
Description
Brand Name: Palbace
Generic Name: Palbociclib
Strength: 125mg
Packing: 21 Capsules in a bottle
Form: Tablets
Palbace125Mg is generally used in combination with letrozole or fulvestrant (Faslodex) for treating certain types of advanced breast cancer in postmenopausal women. It is also given in combination with another cancer medicine, either letrozole (Femara) or fulvestrant (Faslodex).
Palbace is a renamed version of the drug Ibrance for the Indian market. It is verified by the US Food and
Drug Administration (FDA). In clinical studies, palbociclib appeared to increase survival time of patients.
Palbace comes in capsule form in 125 mg dose. 1 pack has 21 capsules.
How Palbace125Mg capsules works ?
Palbace 125mg capsule is an anti-cancer medication. It works by busy bodied with a enzyme, a sort of supermolecule within the body that helps management biological process. This stops cancer cells from dividing and growing.
It is additionally won't to treat patients with bound kinds of carc
Presently, In the US, around 12% of women develop breast cancer over the course of their lifetime. In Canada, an estimated 26,900 women were expected to be diagnosed with breast cancer in 2019 and breast cancer accounts for nearly 25% of new cases of cancer among Canadian women. Download complete report summary @
http://bit.ly/2vsEa1D
American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its
medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis.
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon)
and rectum.
The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food,
and subsequently, it can be taken daily either with or without food.
According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking
etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740
patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.
Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant
patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company.
As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said
GlobalData.
According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at
a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025.
Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses.
However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space."
Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the
potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins,
niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).